European Biotech Acquisition Corp. Warrant
EBACW
EBACW was delisted on the 2nd of March, 2023.
0 hedge funds and large institutions have $0 invested in European Biotech Acquisition Corp. Warrant in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 32 closing their positions.
100% less funds holding
Funds holding: 32 → 0 (-32)
100% less capital invested
Capital invested by funds: $1.16M → $0 (-$1.16M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 32
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$672K |
| 2 |
AGC
Angelo Gordon & Co
New York
|
-$135K |
| 3 |
CS
Clear Street
New York
|
-$65K |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$57.6K |
| 5 |
TCSAM
Tyrus Capital S.A.M.
Monaco
|
-$39.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
26
Atalaya Capital Management
New York
| – | -$3.33K | -13,333 | Closed |
|
|
OAC
27
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$2.92K | -11,666 | Closed |
|
|
VI
28
Vestcor Inc
Fredericton,
New Brunswick, Canada
| – | -$3K | -11,666 | Closed |
|
|
CCA
29
Castle Creek Arbitrage
Avon,
Colorado
| – | -$2.71K | -10,681 | Closed |
|
|
AA
30
Ancora Advisors
Cleveland,
Ohio
| – | -$1K | -2,332 | Closed |
|
|
ETH
31
Exos TFP Holdings
New York
| – | -$326 | -1,094 | Closed |
|
32
UBS Group
Zurich,
Switzerland
| – | -$90 | -300 | Closed |
|
EBACW Hedge Fund Activity: Q1 2023 in Review
0 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Warrant (EBACW) for Q1 2023, worth a combined $0 — down 100% from $1.16M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of EBACW and 0 opened new positions — a net loss of 32 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $672K sold.
- 0 institutional investors held European Biotech Acquisition Corp. Warrant (EBACW) as of Q1 2023, down from 32 in Q4 2022.
- Funds reported $0 of European Biotech Acquisition Corp. Warrant stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new European Biotech Acquisition Corp. Warrant positions in Q1 2023 and 32 closed out, a net change of -32 holders.
- The largest European Biotech Acquisition Corp. Warrant seller in Q1 2023 was Radcliffe Capital Management, an estimated $672K sold.
Based on aggregated 13F filings for Q1 2023.